Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Epirubicin in Advanced Gastric Cancer
NCT00375999Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Sep 2006
- Primary completion
- Dec 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel and epirubicin in gastric cancer (GC), sponsored by Yonsei University. Primary endpoints: Overall Response Rate and Time to Response. Started Sep 2006; status: completed.
02
Drugs
docetaxelepirubicin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00375999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00375999.